It is important to add, the fact that only 25 out of the 40...

It is important to add, the fact that only 25 out of the 40 collected samples could be used was due to the patient population recruited initially ("Participants may have Grades C and D aGVHD involving the skin, liver and/or gastrointestinal (GI) tract or Grade B aGVHD involving the liver and/or GI tract, with or without concomitant skin disease." - https://clinicaltrials.gov/study/NCT02336230) vs. the high risk sub-group (based on MAGIC serum biomarkers, high risk, reflecting active gastrointestinal inflammation and high risk for 6-month NRM) of the sub-group that was filtered out as a result of prior Osiris/MSB trials - could be called a hindsight 20/20 insight.

This is where the FF delay may have not been entirely bad and may have saved us a some money running a trial that may have targeted too broad of a patient population, also potentially requiring a further sub-sub-subgroup post hoc analysis. Instead, the P2 trial is aiming to recruit:
"HR-aGvHD must meet one of the following clinical features within 72 hours prior to randomization: (a) high-risk as per Refined Minnesota Criteria; OR (b) One of the following: (i) isolated stage 2 involvement of the lower GI tract; (ii) Stage 1 lower GI tract disease with skin involvement."
https://clinicaltrials.gov/study/NCT05643638?term=cynata&city=&checkSpell=false&rank=1

Some may consider that "$50 million in near-term cash and stock and up to $50 million more in milestones" saved - if KK is correct.